MedTrace Logo

RING - Rituximab for Lupus Nephritis With Remission as a Goal

NCT01673295 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2015-05-28

No results posted yet for this study

Summary

OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (≥1g/d) despite at least 6 months of standard of care (SOC).

STUDY DESIGN Investigator-initiated randomized international open multicentric 104-week study.

Conditions

Interventions

DRUG

RTX infusions

RTX + Standard of Care

OTHER

Standard of Care

Standard of Care only

Sponsors & Collaborators

  • Frédéric A. Houssiau, MD, PhD

    lead OTHER

Principal Investigators

  • Frédéric A Houssiau, MD PHD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-11-30
Completion
2016-11-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673295 on ClinicalTrials.gov